Cosmo Pharmaceuticals N.V. today announced the details of its successful phase III clinical trial of LuMeBlue™ which will be presented and discussed at its R&D day in Zurich today.
Cosmo Pharmaceuticals N.V. today announced the details of its successful phase III clinical trial of its new antibiotic Zemcolo, which will be presented and discussed at its R&D day in Zurich today.
SYGNIS AG today announced it had been granted broad patents in Europe and China.
joimax ®, .... again exhibited at Chinese Orthopedic Association (COA), which has taken place from Nov 17 th to 20 th , 2016 at China National Convention Center in Beijing, China.
SYGNIS AG today announced the attendance at two major German investor conferences in November and December 2016.
SYGNIS AG today announced the launch of its TruePrimeTM Liquid Biopsy Kit, a ready to use amplification kit for ct-DNA (circulating tumor DNA), to be used in the detection, analysis and monitoring of early tumor stages.
Cosmo Pharmaceuticals N.V. announced that its phase III pivotal clinical trial of LuMeBlue™ for the detection of adenomas during colonoscopy has successfully met the primary endpoint. The trial completes the data set necessary for the registration of the product both in the US and EU.
joimax® ... today announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Vaporflex® and Legato ® electrosurgical probes with radiowave technology for open and endoscopic spine surgery.
SYGNIS AG today reported results for the nine months ended September 30, 2016.
CureVac AG today announced that the company secured a total of $29.5 million in a financing led by new investors BadenWürttembergische Versorgungsanstalt für Ärzte, Zahnärzte und Tierärzte (via the LBBW Asset Management Investmentgesellschaft mbH, Stuttgart) and Landeskreditbank Baden-Württemberg.
CureVac AG today announced that it has been granted a patent (patent No. EP2101823) by the European Patent Office providing broad patent protection for the Company’s RNAntibody® technology.
Apogenix, ... today announced that the final data from the Phase I clinical trial evaluating the safety and efficacy ... of APG101 in lower (low to intermediate) risk patients with myelodysplastic syndromes (MDS) will be presented at the upcoming ... ASH Annual Meeting & Exposition being held December 3-6, 2016 in San Diego, CA, USA.
Public soft loans of €1.2 million and grants of € 0.75 million to fund R&D collaboration of SYGNIS AG with the Spanish National Center for Molecular Biology, San Carlos Hospital and the R&D foundation Juan Dominguez
WILEX AG today announced that its subsidiary Heidelberg Pharma GmbH, Ladenburg, Germany, entered into a research collaboration with Nordic Nanovector ASA, Oslo, Norway (Ticker: NANO) ...
Cosmo Pharmaceuticals NV. will present to its shareholders, analysts and the financial press a comprehensive update on the results of the phase III clinical trials of LuMeBlue™ and Rifamycin and the consequent strategy at its R&D Day to be held November 29, starting at 15:00 CET at the Sonnenberg Convention Center in Zurich.
Cassiopea SpA announced today the results of its proof of concept trial of its novel topical antibiotic CB-06-01 in subjects with moderately to severe acne and the decision to proceed with further development.
WILEX AG today signed a subordinated loan agreement for a total amount of up to EUR 3.7 million with its main shareholder dievini Hopp BioTech holding GmbH & Co. KG, Walldorf, Germany (dievini).
SYGNIS AG today announced the launch of CovCheckTM, a ready to use quality control tool for whole genome amplification (WGA) coverage to determine the quality and integrity of the amplified DNA.
CureVac AG, the most clinically advanced mRNA company, today announced the appointment of Pierre Kemula as Chief Financial Officer (CFO).
Edison Investment Research Limited has published a research update on SYGNIS AG entitled “Bigger, stronger, faster”.
WILEX AG today announced that its subsidiary Heidelberg Pharma, has signed an agreement with Celonic AG, Basel, Switzerland, a specialist in the development and manufacturing of biologics (CDMO).
SYGNIS AG today announced that Navicyte Scientific, part of SYGNIS Group in the US, and the ... ECACC, part of Public Health England, an agency of the United Kingdom Department of Health have entered into a collaboration agreement for licensing and distributing the Caco-2 cell line to commercial companies.
WILEX AG today announced that its subsidiary Heidelberg Pharma GmbH signed an exclusive option agreement with the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) in Berlin covering various BCMA antibodies.
joimax®, the expert in endoscopic minimally invasive spine surgery, is pleased to announce another publication on its technologies to be released in World Neurosurgery (2016).
SYGNIS AG today announced the appointment of Heikki Lanckriet, PhD, currently Chief Executive Officer (CEO) of Expedeon Holdings Ltd., as co-CEO and Chief Scientific Officer (CSO).
SYGNIS AG today announced its financial results for the first six months ended 30 June 2016 and provided a business update.
Cassiopea SpA announced today its half-year results for the period ended 30 June 2016.
SYGNIS AG today announced that the Company has successfully completed its rights offering and the subsequent private placement.
WILEX AG today published its financial report on the first six months of 2016.
CureVac AG ... today announced that a study of its RNActive® technology was published in the renowned, peer-reviewed journal Vaccine.
SYGNIS AG today announced the global launch of TruePrime™ Single Cell WGA Kit V2 for whole genome amplification (WGA) from a broader range of cell types and an increased number of applications.
Today, PAION AG, a specialty pharma company, and Cosmo Technologies Ltd., a subsidiary of Cosmo Pharmaceuticals N.V., (“Cosmo”) entered into a license agreement for remimazolam.
SYGNIS AG today announced that it has developed a new tool in its TruePrime product line to detect and amplify fragments of floating DNA derived from tumor cells in the blood.
Apogenix today announced final topline results from a Phase I trial evaluating APG101 in low to intermediate-1 risk transfusion-dependent patients with myelodysplastic syndromes (MDS). The study showed that APG101 was well tolerated.
Cosmo Pharmaceuticals N.V. announced today that Eleview™ had been granted the CE mark and the approval for marketing in the EU.
WILEX AG and the Advanced Proteome Therapeutics Corporation, today announced that Heidelberg Pharma GmbH ... entered into a partnership with the Canadian APC to create a new generation of antibody-drug conjugates (ADCs).
Cosmo announced that all primary and secondary clinical endpoints were attained in the phase III pivotal trial of Rifamycin SV MMX® for Infectious Colitis run by its licensee, Dr. Falk Pharma.
WILEX AG today announced that Professor Andreas Pahl has been appointed to the company’s Executive Management Board to serve as the new Head of Research and Development.
Edison Investment Research Limited has published a research update on the DNA amplification and sequencing tools company SYGNIS AG entitled “Electrifiying Sales Potential”.
Cosmo Pharmaceuticals S.A. announced that its shareholders have approved the merger of Cosmo Pharmaceuticals S.A., Luxembourg into its fully owned subsidiary Cosmo Pharmaceuticals N.V., a public company organized and existing under the laws of Netherlands, having its corporate seat in Amsterdam, Netherlands but its seat of management at Riverside II, Sir John Rogerson’s Quai, Dublin 2, Ireland.
SYGNIS AG today announced its financial results for the first quarter of 2016, ended 31 March 2016.
SYGNIS AG today resolved, with the approval of the Supervisory Board, to acquire Expedeon Holdings Ltd., a privately held UK proteomics company with sales offices in the U.S., UK and Singapore.
Apogenix ... announced today that Chief Executive Officer Thomas Hoeger, Ph.D., will present at Bio€quity Europe 2016 and at the Jefferies 2016 Healthcare Conference.
joimax® ... is celebrating its 15 th anniversary worldwide in 2016 starting at AANS in Chicago combined with a joimax® Senior Faculty Meeting.
SYGNIS AG today reported results for the fiscal year ending December 31, 2015.
The Executive Management Board of WILEX AG today decided – with the Supervisory Board’s approval – to set the final scope of the rights issue to be executed to a total of 2,248,272 new shares.
Cosmo Pharmaceuticals S.A. announced that the board of directors has approved the merger of Cosmo Pharmaceuticals S.A., Luxembourg into its fully owned subsidiary Cosmo Pharmaceuticals N.V., a public company organized and existing under the laws of Netherlands, having its corporate seat in Amsterdam, Netherlands but its seat of management at Riverside II, Sir John Rogerson’s Quai, Dublin 2, Ireland.
WILEX AG today announced its plan to reduce the number of Supervisory Board members from six to five
CureVac ... today announced the expansion of its external Scientific Advisory Board (SAB) to guide the company in this important period of extensive clinical development and in its portfolio prioritization process.
Apogenix ... announced today that the data published in the current issue of Oncotarget demonstrate that APG101 rescues the production of red blood cells (erythropoiesis) in bone marrow samples from patients with lower-risk myelodysplastic syndromes (MDS).
Cosmo Pharmaceuticals S.A. today announced its results for the year ended 31 December 2015.
WILEX AG today published its financial results and annual report for the 2015 financial year (1 December 2014 - 30 November 2015)
CureVac ... today announced the appointment of three seasoned industry experts to its supervisory board.
SYGNIS AG today announced that it will present its revolutionary novel multi displacement amplification (MDA) technology TruePrime™ at two upcoming renowned scientific conferences
SYGNIS AG today announced that it will participate in the Festival of Genomics in London, UK, from January 19 to 21, 2016.
Apogenix ... announced today that it has received Notices of Allowance from the U.S. Patent and Trademark Office for two key patents for lead immuno-oncology candidate APG101.
WILEX AG today announced that its partner Link Health Co., Guangzhou, China, submitted an IND application to the CFDA to conduct a Phase I dose escalation study with the cancer compound MESUPRON®.
SYGNIS AG today announced that it has globally launched the SunScript™ One Step RT-qPCR Kit on December 21, 2015.